Conditions: Type 2 Diabetes Mellitus
Keywords: Phase 1b type 2 diabetes metformin background PF-04937319
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 33
Healthy volunteers: no

Brief summary:
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: PF-04937319 once-daily intervention 2: PF-04937319 split-dose intervention 3: Sitagliptin once-daily
Intervention descriptions: intervention 1: Tablets, 300 mg once-daily with breakfast, 14-days intervention 2: tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days intervention 3: tablets, 100 mg once-daily with breakfast, 14-days

Protocol document: